This article presents a subgroup analysis of the phase 3 SOLSTICE clinical trial, focusing on solid organ transplant recipients treated with maribavir for refractory cytomegalovirus (CMV) infection. The study compared maribavir to investigator-assigned therapy, assessing efficacy in CMV viremia clearance and safety, including treatment-emergent adverse events and the development of maribavir resistance. Results showed maribavir's superiority in CMV clearance across various transplant types and fewer treatment discontinuations compared to standard treatments. The findings support maribavir's effectiveness and safety profile in this specific patient population. Limitations of the open-label design and sample size are acknowledged.
PMID: 39613120
Blumberg EA, Witzke O, Harber M, et al. Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: Subgroup analysis of the phase 3 randomized SOLSTICE study. J Heart Lung Transplant 2024;S1053-2498(24)01971-5.
Created with NotebookLM by Google so there may be mistakes and/or errors.
